

22nd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy October 1-4, 2020

Chairs: J. Cortes, T.P. Hughes, D.S. Krause

**Co-Organizers: R. Bhatia, T. Brümmendorf, M. Copland, M. Deininger, O. Hantschel, F-X. Mahon, D. Perrotti,
J. Radich, D. Réa**

**Advisory Committee: J. Apperley, S. Branford, C. Gambacorti-Passerini, F. Guilhot, R. Hehlmann,
P. Laneuville, G. Saglio, C. Schiffer, S. Soverini, P. Valent, R. Van Etten**

*This program is presented according to Central European Summer Time (CEST).
Please check the corresponding hours in your time zone.*

Thursday, October 1, 2020

14:00-14:10	WELCOME	Jorge Cortes (Augusta)
14:10-14:20	iCMLf - A REVIEW	Tim P. Hughes (Adelaide)
14:20-14:53	SPECIAL INTRODUCTORY LECTURE Chair: Jerry Radich (Seattle)	
14:20-14:23	<i>Introduction</i>	
14:23-14:43	Finding relapse-fated cells at diagnosis and targeting relapse before it evolves	John Dick (Toronto)
14:43-14:53	<i>Discussion</i>	
14:53-16:40	SCIENTIFIC SESSION 1: TOP SCORING ABSTRACTS 2020 Chairs: Brian Huntly (Cambridge), Francois -Xavier Mahon (Bordeaux)	
14:53-14:56	<i>Introduction</i>	
14:56-15:08	Targeted RNA-Based Gene Sequencing Identifies Mutated Blood Cancer-Linked Genes at Diagnosis of CML That Are Associated with Treatment Failure	Susan Branford (Adelaide)
15:08-15:20	Tgfβr - SMAD3 Signaling Protects CML and Other Myeloid Malignancies from Synthetic Lethality Triggered By PARP Inhibitor in Bone Marrow Microenvironment	Bac Viet Le (Warsaw/Philadelphia)
15:20-15:32	Interim Analysis from the Optic Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib	Jorge Cortes (Augusta)
15:32-15:44	Deceiving and Drugging BCR-ABL1 Compound Mutants: Pairing a Conformational Influencer with Asciminib or an Asciminib Proteolysis-Targeting Chimera (PROTAC)	Thomas O'Hare (Salt Lake City)

15:44-15:56	Therapeutic Inhibition of Malignant FcγRIIb-Induced BTK Activation Targets Leukemic Stem Cells in Chronic Myeloid Leukemia	Mirle Schemionek (Aachen)
15:56-16:08	Molecular Status 36 Months after TKI-Discontinuation in CML Is Highly Predictive for Later Loss of MMR - a Report from after-SKI.	Johan Richter (Lund)
16:08-16:20	Protein Transfer between CML and Bone Marrow Stromal Cells: Functional Meaning and the Involvement of Tnts	Marta Kolba (Warsaw)
16:20-16:40	<i>Discussion</i>	
16:40-16:50	<i>Break</i>	
16:50-17:23	TESSA HOLYOAKE MEMORIAL LECTURE: SPECIAL LECTURE Chair: Steffen Koschmieder (Aachen)	
16:50-16:53	<i>Introduction</i>	
16:53-17:13	Understanding and targeting the stem cell origins of myeloid malignancies	Ulrich Steidl (New York)
17:13-17:23	<i>Discussion</i>	
17:23-19:10	SCIENTIFIC SESSION 2: STEM CELLS AND THE MICROENVIRONMENT Chairs: Daniela Krause (Frankfurt) and Ram Thakur (Lund)	
17:23-17:26	<i>Introduction</i>	
17:26-17:41	<i>Keynote Presentation</i> Regulation of hematopoietic stem and progenitor cells by the bone marrow microenvironment	Ralf Adams (Munster)
17:41-17:51	<i>Discussion</i>	
	<i>Selected Abstracts</i>	
17:51-18:03	The Role of the Autophagy Adaptor Protein PLEKHM1 in the Leukaemic Bone Marrow Microenvironment	Christina Karantanou (Frankfurt)
18:03-18:15	Features of BCR-ABL1 Driven Myeloproliferative Disease in a CML Mouse Model Are Dependent on LSC Age and Fitness	Hassan Almasoudi (Glasgow)
18:15-18:27	Murine Hematopoietic and Leukemic Stem/Progenitor Cell Lines As Model Systems for Bcr/Abl Driven Disease	Veronika Sexl (Vienna)
18:27-18:39	Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Drug-Resistant CML Stem/Progenitor Cells	Andrew Wu (Vancouver)
18:39-18:51	The Spliceosome: An Another Regulating System of Gene Expression Deregulated in CP-CML CD34+CD15- Cells	Benjamin Lebecque (Clermont-Ferrand)
18:51-19:10	<i>Discussion</i>	

19:10-19:50	JANET ROWLEY PRIZE CEREMONY	
19:10-19:20	JANET ROWLEY PRIZE PRESENTATION Presenter: Rob Welner (Birmingham) Awardee 2020: Ravi Bhatia (Birmingham)	
19:20-19:40	JANET ROWLEY PRIZE: SPECIAL LECTURE (2) Chair: Rob Welner (Birmingham)	
	The seed and the soil – the leukemia stem cell in its niche and the quest for cure	Ravi Bhatia (Birmingham)
19:40-19:50	<i>Discussion</i>	

Friday, October 2, 2020

11:30-12:15	SCIENTIFIC SESSION 3: IMMUNOLOGY AND INFLAMMATION Chair: Shinya Kimura (Saga)	
11:30-11:33	<i>Introduction</i>	
	Selected Abstracts	
11:33-11:45	Sterile Inflammation in Normal Hematopoiesis and Leukemia	Pablo Llavona (Frankfurt)
11:45-11:57	Immunosuppressive Polarization of T Cell Subsets in Spleen and Bone Marrow of Mice with CML-like Disease	Julian Swatler (Warsaw)
11:57-12:15	<i>Discussion</i>	
12:15-14:00	Lunch	

13:00-14:00 **SATELLITE SYMPOSIUM:
RECENT HIGHLIGHTS IN CML: WHAT HAVE WE LEARNED IN 2020?**
Chair: Philippe Rousselot (France)
Speakers: Mario Tiribelli (Italy), Jorge Cortes (USA)

This educational symposium is organized and funded by Incyte Biosciences International Sàrl

14:00-15:33	SCIENTIFIC SESSION 4: THE BIOLOGY OF BLAST PHASE Chair: Adam Mead (Oxford)	
14:00-14:03	<i>Introduction</i>	
14:03-14:18	Keynote Presentation CRISPR predictions about relapse in CML	Daniel Bolon (Amherst)
14:18-14:28	<i>Discussion</i>	
	Selected Abstracts	
14:28-14:40	RUNX1 Mutations in Blast Phase Chronic Myeloid Leukemia	Shady Adnan Awad (Helsinki)

14:40-14:52	H3K36ME3 Loss in Chronic Myeloid Leukemia Patients in Blast Crisis Is Mediated by an Unbalanced SETD2/KDM4A Activity and CAN be Therapeutically Targeted	Manuela Mancini (Bologna)
14:52-15:04	Releasing the Brakes on Apoptosis: Investigating Combinations of BH3 Mimetics and Nilotinib in Blast Phase CML	Narissa Parry (Glasgow)
15:04-15:16	Discovery of Novel CIP2A Variant (NOCIVA) and its Clinical Association with Myeloid Leukemias	Eleonora Mäkelä (Turku)
15:16-15:33	<i>Discussion</i>	

15:35

Biology Posters - Mentored Poster Walk 1

Biology Poster Walk Leaders: Sin Tiong Ong (Singapore), Stéphane Prost (Fontenay-aux-Roses)

15:35 – 16:35

CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

Clinical trial design	Donald Berry (Houston) and Joëlle Guilhot (Poitiers)
New drugs under development	Jorge Cortes (Augusta) and Tim Hughes (Adelaide)

16:35-16:45

Convene in the Main Conference Hall

16:45 -18:20

SPECIAL SYMPOSIUM ON ONCOIMMUNOLOGY IN HEMATOLOGIC MALIGNANCIES

Chairs: Jorge Cortes (Augusta), Kimmo Porkka (Helsinki)

16:45-16:55	Introductory overview – concepts and challenges	
16:55-17:07	<i>Leukemia vaccines</i>	David Scheinberg (New York)
17:07-17:19	<i>Past, present and future of CAR-T cell therapy for AML?</i>	Saar Gill (Philadelphia)
17:19-17:31	<i>Bi-specific and allogeneic CAR-T</i>	Xianxin Hua (Philadelphia)
17:31-17:43	<i>Checkpoint inhibitors</i>	Justin Kline (Chicago)
17:43-17:55	<i>Bispecific antibodies in myeloid leukemias</i>	Roland Walter (Seattle)
17:55-18:20	General Discussion	

18:20-18:53

SPECIAL LECTURE (3):

Chair: Rick Van Etten (Irvine)

18:20-18:23	<i>Introduction</i>	
18:23-18:43	CML blast crisis and the microenvironment	Tannishtha Reya (San Diego)
18:43-18:53	<i>Discussion</i>	

18:55 – 19:55

CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)

Hematopoiesis

Timm Schroeder (Basel)

Immunological approaches
to the treatment of leukemia

Roland Walter (Seattle) and David Scheinberg (New York)

Saturday, October 3, 2020

08:50-10:50

**WORKSHOP FOR NON-CLINICAL SCIENTISTS #1
PROTEOMICS / SECRETOMICS**

Chairs: Oliver Hantschel (Marburg) and Vignir Helgason (Glasgow)

08:50-08:55

Introduction

Oliver Hantschel (Marburg)
and Vignir Helgason (Glasgow)

08:55-09:20

An integrated platform for biomarker and
drug target discovery using proteomics

Anthony Whetton (Manchester)

09:20-09:45

MS-proteomics to uncover the complexity
and function of the cell secretome

Sara Zanivan (Glasgow)

09:45-10:10

Investigating secretome and sheddome
composition with proteomic approaches

Oliver Schilling (Freiburg)

10:10-10:40

Discussion

10:40-10:50

Conclusion

11:00-11:40

JOHN GOLDMAN PRIZE CEREMONY

11:00-11:10

JOHN GOLDMAN PRIZE PRESENTATION

Presenter: Hemant Malhotra (Jaipur)

Awardee 2020: Jane Apperley (London)

11:10-11:30

JOHN GOLDMAN PRIZE: SPECIAL LECTURE (4)

Chair: Hemant Malhotra (Jaipur)

CML and me: reflections on the roadmap to cure

Jane Apperley (London)

11:30-11:40

Discussion

11:40-13:10

SCIENTIFIC SESSION 5: NEW TREATMENT STRATEGIES

Chair: Gianantonio Rosti (Bologna), Tim Brummendorf (Aachen)

11:40-11:43

Introduction

11:43-11:58

Keynote Presentation

Citius, Altius, Fortius ?

Andreas Hochhaus (Jena)

11:58-12:08

Discussion

Selected Abstracts

12:08-12:20

A Novel Oral Demethylating Agent, or-2100, in Combination
with Tyrosine Kinase Inhibitors Overcomes Resistance in Chronic
Myeloid Leukemia

Kazuharu Kamachi (Saga)

12:20-12:32	Targeting Integrated Stress Response Combined with Imatinib As a Novel Strategy to Eradicate Imatinib-Resistant CML Cells	Katarzyna Piwocka (Warsaw)
12:32-12:44	Activity of Vodobatinib, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) in CML Patients Failing TKI Therapies Including Ponatinib	Jorge Cortes (Augusta)
12:44-12:56	Radotinib Treatment for Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to or Intolerant of BCR-ABL1 Tyrosine-Kinase Inhibitors: 60-Month Follow-up of a Phase 2 Study	Sung-Hyun Kim (Busan)
12:56-13:10	<i>Discussion</i>	

13:10-14:50 *Lunch*

13:20-14:50 **SATELLITE SYMPOSIUM:
TRAVELING THROUGH THE UNSOLVED NEEDS IN CML: TOWARDS NEW STRATEGIES**
Chair: Andreas Hochhaus (Jena)
Speakers: Valentin Garcia-Gutiérrez (Madrid), Massimo Breccia (Roma), Delphine Réa (Paris)

This educational symposium is organized and funded by Novartis Oncology

14:50-15:00 *Convene in the Main Conference Hall*

15:00-15:20 **ESH INTERNATIONAL JOHN GOLDMAN RESEARCH AWARD CEREMONY**

15:00-15:10 **Presenter:** Hervé Dombret (Paris), ESH President

15:10-15:20 **Awardee 2020:** Vaidehi Krishnan (Singapore)
High dimensional single-cell analysis to predict TFR at the time of CML diagnosis

15:20-16:55 **SCIENTIFIC SESSION 6: TREATMENT-FREE REMISSION**

Chair: Dragana Milojkovic (London)

15:20-15:23 *Introduction*

15:23-15:38 **Keynote Presentation** Susanne Saussele (Mannheim)
Strategies for optimal TFR rates in CML

15:38-15:48 *Discussion*

Selected Abstracts

15:48-16:00 The rate of *BCR-ABL1* decline after TKI commencement is a strong predictor of sustained Treatment Free Remission Naranie Shanmuganathan (Adelaide)

16:00-16:12 High Level of Successful TKI Discontinuation Outside Clinical Trials - a Population-Based Study from the Swedish CML Registry Johan Richter (Lund)

16:12-16:24 Efficacy and Safety of Pioglitazone in a Phase II Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia Patients Katia Pagnano (Campinas)

16:24-16:36	Update of the French Spirit Trial with a Detailed Focus on Treatment Free Remission	François Guilhot (Poitiers)
16:36-16:55	<i>Discussion</i>	
16:55-17:05	Break	
17:05-18:50	SCIENTIFIC SESSION 7: TREATMENT-FREE REMISSION - PREDICTIVE FACTORS Chair: Delphine Réa (Paris)	
17:05-17:08	<i>Introduction</i>	
17:08-17:23	Keynote Presentation Successful TFR in CML: is it predictable?	Agnes Yong (Adelaide)
17:23-17:33	<i>Discussion</i>	
	Selected Abstracts	
17:33-17:45	BCR-ABL1 Transcript Doubling Time after Imatinib Discontinuation for Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase: Early Predictive Surrogate for Treatment-Free Remission Failure after Imatinib Discontinuation	Dennis Kim (Toronto)
17:45-17:57	Chronic Myeloid Leukemia Patients' Concerns during Phase I of the Treatment-Free Remission Journey: Considerations Between Patients and Doctors in the Different CML Advocates Network Regions	Giora Sharf (Netanya)
17:57-18:09	Best Duration of Deep Molecular Remission to Achieve Therapy-Free Remission in Chronic Myeloid Leukaemia	Robert Gale (London)
18:09-18:21	Risk Factor Analysis for Treatment-Free Remission Failure after Imatinib Discontinuation in Patients with Chronic Myeloid Leukemia in Chronic Phase: The Optimal Duration of Total Imatinib Treatment and MR4 Response	Dennis Kim (Toronto)
18:21-18:33	Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: An International Registry of Childhood Chronic Myeloid Leukemia (I-CML-Ped) Study	Frédéric Millot (Poitiers)
18:33-18:50	<i>Discussion</i>	
18:50-19:23	SPECIAL LECTURE (5): Chair: Giovanni Martinelli (Meldola)	
18:50-18:53	<i>Introduction</i>	
18:53-19:13	Human evolutionary genomic medicine	Melissa Ilardo (Salt Lake City)
19:13-19:23	<i>Discussion</i>	

Sunday, October 4, 2020

14:30-16:30	WORKSHOP FOR NON-CLINICAL SCIENTISTS #2 ARTIFICIAL INTELLIGENCE / MACHINE LEARNING Chairs: Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)	
14:30-14:35	Introduction	Michael Deininger (Salt Lake City) and Daniela Krause (Frankfurt)
14:35-15:00	Long-term single-cell quantification: new tools for old questions	Timm Schroeder (Basel)
15:00-15:25	Computational Pathology: Towards Precision Medicine	Andrew Janowczyk (Cleveland)
15:25-15:50	Learning to Care: Artificial Intelligence Meets Clinical Practice	Jeffrey Humpherys (Salt Lake City)
15:50-16:20	Discussion	
16:20-16:30	Conclusion	

14:30 – 15:30	CONCURRENT MEET-THE-EXPERT SESSIONS (pre-registration required)	
	Understanding and analyzing the new ELN recommendations	Andreas Hochhaus (Jena) and Michael Mauro (New York)

15:30-16:30	<i>Clinical Posters - Mentored Poster Walk 2</i> Clinical Poster Walk Leaders: Franck Nicolini (Lyon), Pierre Laneuville (Montreal)	
16:30- 17:03	SPECIAL LECTURE (6): Chair: Catriona Jamieson (La Jolla)	
16:30-16:33	<i>Introduction</i>	
16:33-16:53	Single cell RNA sequencing in MPN	Bethan Psaila (Oxford)
16:53-17:03	<i>Discussion</i>	
17:03-18:20	DEBATE: “SWITCH TO A MORE POTENT DRUG TO GAIN ELIGIBILITY FOR TFR?” Chair: Philippe Rousselot (Versailles)	
17:03-17:06	<i>Introduction</i>	
17:06-17:10	Voting	
17:10-17:30	Against:	Charles Schiffer (Detroit)
17:30-17:50	For:	Giuseppe Saglio (Turin)
17:50-18:20	Voting and Discussion	

18:20-19:00	iCMLf PRIZE CEREMONY	
18:20-18:30	iCMLf PRIZE PRESENTATION: Presenter: Jerry Radich (Seattle) Awardee 2020: Sabira Kurtovic (Sarajevo)	
18:30-18:50	iCMLf PRIZE: SPECIAL LECTURE (7) Chair: Jerry Radich (Seattle)	
	CML management in war and peace: lessons that shaped future approaches	Sabira Kurtovic (Sarajevo)
18:50-19:00	<i>Discussion</i>	
19:00-20:20	SCIENTIFIC SESSION 8: TKI SAFETY Chair: Javier Pinilla-Ibarz (Tampa)	
19:00-19:03	<i>Introduction</i>	
19:03-19:18	Keynote presentation Novel trial designs	Donald Berry (Houston)
19:18-19:28	<i>Discussion</i>	
	<i>Selected Abstracts</i>	
19:28-19:40	Cellular Metabolic Flexibility to Explain Interindividual Susceptibility for Tyrosine Kinase Inhibitor-Induced Muscle Complaints	Lando Janssen (Nijmegen)
19:40-19:52	Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib Phase 2 PACE Trial (NCT01207440) in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia	James Januzzi (Boston)
19:52-20:04	High Body Mass Index (BMI) and Treatment Responses in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Receiving First-Line Dasatinib or Imatinib: Exploratory Post Hoc Analysis of the Phase 3 DASISION Study	Massimo Breccia (Rome)
20:04-20:20	<i>Discussion</i>	
20:20	<i>Closing remarks</i>	